S ystolic heart failure (HF) is both an inflammatory and prothrombotic condition, as evidenced by elevated levels of circulating cytokines and an increased risk of thromboembolic events. 1 Platelets are the major cellular component of thrombosis, 2 and patients with HF have enhanced platelet activation, as reflected by increased whole blood aggregation, 3 high mean platelet volume, 4 and increased platelet P-selectin surface exposure. 5 In addition to roles in hemostasis and thrombosis, platelets are also able to regulate the activity of other cell types, and cross-talk between monocytes and platelets is reflected by formation of monocyte-platelet aggregates (MPAs). MPAs have been shown to be a more sensitive marker of platelet activation than platelet surface P-selectin, because degranulated platelets rapidly shed P-selectin but still function in the circulation. 6, 7 Monocyte aggregation with platelets is accompanied by monocyte activation, resulting in increased cytokine production, expression of cell-adhesion molecules, and the release of matrix metalloproteinases, all of which may be important in collagen breakdown and left ventricular (LV) dysfunction. 8 Even in the absence of platelet interaction, monocytes play an important role in inflammation and thrombosis, performing vital functions such as phagocytosis, cytokine production, and tissue repair, 9 as well as being a major source of blood tissue factor. 10 The specific role of monocytes in HF is largely unknown, although monocyte levels are increased in patients who develop LV dysfunction after myocardial infarction (MI), and a recent study also demonstrated increased monocyte numbers in patients with stable systolic HF. 11 Furthermore, monocytes are heterogeneous and consist of distinct subpopulations with differing phenotype and functional characteristics. 12, 13 These subsets can be defined by flow cytometry according to differential expression of surface markers, giving rise to classic CD14++CD16-CCR2+ (Mon1), intermediate CD14++CD16+CCR2+ (Mon2), and nonclassic CD14+CD16++CCR2-(Mon3) subsets. 13 
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Although data on these subsets in HF are limited, the Mon2 subset has a distinct gene expression profile compared with the other subsets and particularly express genes linked to inflammation and angiogenesis, which may be important in tissue remodeling. 14 These findings are also in accordance with recent data demonstrating high expression of cell surface receptors associated with angiogenesis and tissue repair on Mon2, as well as their abundance in bone marrow. 13 
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MPAs are increased in numerous conditions associated with ischemia and thrombosis, such as acute MI, 7,15 limb ischemia, 16 and stroke. 17 However, an interaction between monocytes (and their individual subsets) and platelets has not been studied in HF, and the possible impact on clinical outcome is unknown.
In this study, we aimed to compare levels of MPAs in patients with acute HF (AHF), stable HF (SHF), and control subjects with normal LV function, as well as dynamics of monocyte-platelet interactions and their association with clinical outcomes in patients with AHF.
Methods

Cross-Sectional Study
Fifty-one consecutive patients admitted to hospital with ischemic systolic AHF were recruited. AHF was defined in accordance with the European Society of Cardiology guidelines as the rapid onset/progression of HF symptoms and signs secondary to abnormal cardiac function requiring hospital admission. 18 All of the AHF patients had documented LV ejection fraction (LVEF) ≤40% on echocardiography or left ventriculography with New York Heart Failure association class IV on admission. Patients presenting with an acute coronary syndrome were excluded. Patients with AHF were compared with the following: (1) 42 subjects with ischemic SHF (LVEF ≤40% and no deterioration in clinical status, hospital admission, or change in medication during the preceding 6 months); (2) 44 patients with stable coronary artery disease (CAD), having MI >6 months before the recruitment or angiographically documented coronary artery stenosis >50%) with LVEF >50%; and (3) 40 healthy controls (HCs) free from known morbidities and not taking medications. To minimize potential confounders, underlying CAD was the etiology of HF in all of the patients. For all of the study groups, exclusion criteria included factors that could affect monocyte count (infectious and inflammatory disorders, cancer, hemodynamically significant valvular heart disease, atrial fibrillation, renal failure [creatinine >200 µmol/L], steroids, and hormone replacement therapy). Recruitment for all 4 of the study groups was undertaken during an 18-month period (October 30, 2009, to April 30, 2011), and patients were selected from 2 hospital trusts within the West Midlands, United Kingdom.
Nonfasting peripheral venous blood samples were obtained from all of the study subjects with a 21-gauge needle with minimal stasis into commercial tubes (Greiner Bio-One, Gloucestershire, United Kingdom) containing EDTA (for flow cytometric analysis) and sodium citrate (for plasma markers) as anticoagulants and analyzed by flow cytometry within 60 minutes of collection.
Longitudinal Study in Patients With AHF
To assess the dynamics of MPAs in AHF, blood samples were analyzed at the following time points: (1) during the first 24 hours after admission; (2) on the day of hospital discharge; and (3) 3 months after hospital admission. Recruitment began on October 30, 2009 , and all of the patients were followed until July 30, 2011, to register any cases of stroke, MI, rehospitalisation attributed to HF, or all-cause mortality.
The study was performed in accordance with the Helsinki Declaration and approved by the Warwickshire Research Ethics Committee. All of the participants provided written, informed consent.
Flow Cytometry
Flow cytometric analysis was performed using the BD FACSCalibur flow cytometer (Becton Dickinson [BD], Oxford, United Kingdom). We have recently published a reliable flow cytometry method to discriminate and accurately enumerate the 3 monocyte subsets and their aggregates with platelets. 13 The technique is robust and highly reproducible, and the laboratory coefficient of variation for absolute monocyte count and MPA is 1.9%.
Mouse antihuman monoclonal fluorochrome-conjugated antibodies anti-CD16-Alexa Fluor 488 (clone DJ130c, AbD Serotec, Oxford, United Kingdom), anti-CD14-PE (clone MфP9, BD), and anti-CCR2-APC (clone 48607, R&D Systems Europe Ltd, Abingdon, United Kingdom) were mixed with 50 μL of fresh EDTA anticoagulated whole blood in TruCount tubes (BD) containing a strictly defined number of fluorescent count beads. After incubation for 15 minutes, red blood cells were lysed by 450 μL of lysing solution (BD) for 15 minutes, followed by dilution in 1.5 mL of PBS and immediate flow cytometric analysis. Monocytes were selected by gating strategies based on forward and side scatter to select monocytes, side scatter versus CD14 expression to exclude granulocytes, and ungated CD14 versus CD16 expression to exclude natural killer lymphocytes ( Figure 1 ). Subsets were defined as CD14++CD16-CCR2+ (classic, Mon1), CD14++CD16+CCR2+ (intermediate, Mon2), and CD14+CD16++CCR2-(nonclassic, Mon3) monocytes. Absolute counts of monocyte subsets (in cells per microliter) were obtained by calculating the number of monocytes proportional to the number of the count beads according to the manufacturer's recommendations. MPAs were defined as events positive to both monocyte markers (as above) and the platelet marker CD42a (glycoprotein IX; Figure 1 ). The number of events collected was ≥400 events for each monocyte subset and 10 000 count beads.
Plasma Markers
To investigate correlations between MPA and markers of systemic inflammation and monocyte recruitment, plasma levels of interleukin 6 (IL-6) and monocyte-chemoattractant protein 1 (MCP-1) were measured by cytometric bead array technology. The BD FACSCalibur flow cytometer was used for data acquisition, with FCAP Array version 2.0.2 software (Burnsville, MN) for data analysis. Commercially available Human IL-6 Flex Set and Human MCP-1 Flex Set (both from BD) were used according to the manufacturer's recommendations, as reported previously. 15 The lower limits of detection were 1.0 pg/mL for IL-6 and 1.3 pg/mL for MCP-1. Brain natriuretic peptide (BNP) was measured using a commercially available enzyme immunoassay set (human BNP-32, Peninsula Laboratories, LLC, San Carlos, CA) according to the manufacturer's specifications. The interassay and intra-assay coefficients of variation for all of the assays was <5%.
Power Calculation
Based on our previous work, the calculated (based on ANOVA) minimum number of participants in each group required to detect an assumption of minimal difference of 0.5 SD in the count of MPA between the study groups with 80% power (1-β=0.8) with α=0.05 (2-tiled) was n=35. 13
Statistical Analysis
Values were expressed as mean (SD), median (interquartile range [IQR]), or percentages, for normally distributed, nonnormally distributed, and categorical variables, respectively. Cross-sectional comparisons among the 4 study populations were made using a χ 2 test (for categorical variables) and 1-way ANOVA and Kruskal-Wallis test for normally distributed and nonnormally distributed measures, respectively. A post hoc Tukey test was performed to assess intergroup differences, where appropriate. Arithmetical transformation was performed on nonnormally distributed variables before post hoc analysis. Repeated-measures ANOVA for normally distributed data and Friedman test for nonnormally distributed data were used to analyze longitudinal changes in study parameters. For patients with AHF, correlation coefficients were calculated by Pearson and Spearman tests for normally and nonnormally distributed data, respectively. Univariate and multivariate Cox regression analyses were used to determine predictors of the study end point. For multivariate analysis we included predictors identified in the univariate test. Recognizing the relatively small sample size, variables achieving P<0.10 on univariate testing were entered into a multivariate Cox regression analysis. Age was also included in this analysis because of its well-recognised association with mortality. Kaplan-Meier estimates for the distribution of time from index admission to the primary end point were computed, and log-rank analysis was performed to compare event-free survival according to quartiles of MPAs with Mon2. Data analysis was carried out using SPSS 18.0 (SPSS Inc, Chicago, IL) with a P value <0.05 considered statistically significant.
Results
Cross-Sectional Analysis
Relevant demographic and clinical characteristics are summarized in Table 1 . Patients with HF had higher creatinine values than controls (P<0.001), and HCs included fewer cigarette smokers compared with other groups (P<0.001)
Monocyte-Platelet Aggregates
The total MPA count and MPAs associated with Mon1 and Mon2 were significantly increased in the AHF group compared with the 3 control groups (Table 2 and Figure 2 ). MPAs associated with Mon3 were higher in the AHF group compared with HCs (P<0.001) but similar to SHF and CAD groups.
The proportion of Mon1 aggregated with platelets was increased in AHF compared with SHF (P=0.03), CAD (P<0.001), and HCs (P<0.001). There were no differences in the proportion of Mon2 aggregated with platelets across the study groups. A higher percentage of Mon3 aggregated with platelets was seen in the AHF group compared with SHF (P=0.012) and HCs (P<0.001) but not compared with CAD (P=0.22).
Patients with SHF had significantly higher total MPA count compared with HCs (P=0.02), and there was a trend toward higher counts compared with CAD (P=0.07). Similarly, MPAs associated with Mon1 were significantly higher in patients with SHF compared with HCs (P<0.001), but there were no differences when compared with the CAD group (P=0.10). MPAs associated with Mon2 were higher in the SHF group compared with CAD (P=0.04) and HCs (P=0.004). There were no differences between MPAs associated Mon3 when comparing SHF with CAD and HCs.
The proportion of Mon1 aggregated with platelets was higher in the SHF group compared with HC (P=0.01) but was not different compared with CAD (P=0.59). The proportion of Mon2 and Mon3 aggregated with platelets did not differ among SHF, CAD, and HCs.
Longitudinal Analysis
Fifty-one patients admitted with AHF were recruited to the study. Medications did not change during the study period, and, specifically, 80% of patients were taking an antiplatelet drug (aspirin, clopidogrel, or both) at the first time point when blood was taken, with no changes made during the follow-up period. The median length of hospital stay was 8.5 days (IQR, 5.0-12.8 days). None of the patients experienced MI or stroke during follow up, but 20 patients (39.2%) experienced an adverse clinical event during follow-up (15 patients [29.4%] died, and an additional 5 patients [9.8%] were readmitted to the hospital with HF), with a median time to event of 129 days (IQR, 70-209 days). Of those who died, 13 patients died of HF, 1 died from a ruptured abdominal aortic aneurysm, and the cause of death in 1 patient was unknown. The remaining patients were followed up for a median of 387 days (IQR, 223-550 days).
Thirty-six AHF patients (71%) completed all 3 of the blood test time points and were used to analyze changes in MPA parameters over time. For those not completing all 3 of the blood tests, 11 had already reached a clinical end point (death or rehospitalization)m and 4 were lost to follow-up but had not reached the end point according to medical charts. When compared with measurements taken during the first 24 hours of admission, the total MPA count and MPAs associated with ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; BP, blood pressure; CAD, stable coronary artery disease; CCB, calcium channel blocker; COPD, chronic obstructive airways disease; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; HF, heart failure; and LVEF, left ventricular ejection fraction. Normally distributed data are presented as mean (SD), nonnormally distributed data are presented as median (interquartile range).
*Data show acute HF vs stable HF.
Mon1, Mon2, and Mon3 did not change significantly for 3 months of follow-up ( [n=6]). The only parameter to change was a reduction in the percentage of Mon3 aggregated to platelets at 3 months compared with on admission (P=0.009). Table 4 ). In a multivariate Cox regression analysis, Mon2 count remained an independent negative predictor of combined death and rehospitalization after adjustment for age, LVEF, creatinine, and BNP (Table 4 ).
Monocyte-Platelet Aggregates as Predictors of Clinical Outcome
For Kaplan-Meier analysis, patients were grouped by quartiles of MPAs associated with Mon2 ( Figure 3 
Correlation Analysis of MPAs With Plasma Markers and LVEF
In patients admitted with AHF, plasma concentration of IL-6, MCP-1, and BNP were 11 (7-16), 125 (7-16), and 365 pg/mL (108-872 pg/mL), respectively. Counts of MPA with Mon3 significantly correlated with MCP-1 levels (r=0.32; P=0.022). There was no correlation between MPAs and IL-6 or BNP levels (Tables S1 and S2, available in the online-only Data Supplement). The percentage of Mon1 aggregated with platelets negatively correlated with LVEF measured during hospital admission (r=-0.30; P=0.046; Table S2 ).
Discussion
MPAs represent a sensitive marker of both monocyte and platelet activation, and we have shown for the first time that the total MPA count is increased in patients with both AHF and SHF compared with controls with normal LV contractility. Importantly, increased formation of MPAs in AHF is confined to monocytes from the Mon1 and Mon2 subsets and not from the Mon3 subset. We have also shown that MPAs from Mon2 are inversely predictive of adverse outcome in patients admitted to hospital with AHF, independent of age, LVEF, and renal function. The cause of death in the majority of patients was because of worsening of HF, and no patients experienced stroke or MI during follow-up. Thus, an association between clinical outcome and the formation of MPAs seems to be in addition to the acknowledged increased risk of thromboembolism in patients with HF.
It remains unclear why MPAs from Mon2 are increased in AHF compared with controls, and yet patients who have the worst outcomes have the lowest numbers of such complexes. One might speculate that MPAs from this subset of monocytes have beneficial or reparative properties in the myocardium, and a failure to form MPAs in AHF results in a greater insult to the myocardium and, hence, a worse prognosis. Alternatively, circulating MPA levels may not reflect their abundance within the myocardium itself, and low levels of circulating MPAs from Mon2 in those patients who have the worst prognosis may reflect a rapid migration and uptake of these complexes into the myocardium. Indeed, the transendothelial migration of MPAs is associated with a dissociation of the aggregate. 19 Nonetheless, the observational nature of this study does not allow mechanistic insights into the specific roles of MPAs in HF, and further data on the prognostic role of MPAs are required.
Mon2 monocytes are increased in inflammatory conditions, and the formation of MPAs may reflect another marker of their proinflammatory activity. In acute coronary syndrome, MPAs represent a link between inflammation and thrombosis, with increased numbers formed in patients with troponin-positive coronary events, perhaps reflecting instability of coronary plaques and vascular inflammation. [20] [21] [22] In HF, the precise trigger for MPA formation is less clear, although contributing factors are likely to include haemodynamic changes, activation of the renin-angiotensin system, endothelial dysfunction, and increased catecholamines. 23 As well as simply representing a marker of platelet activation, a recent study has shown that the formation of MPAs results in significant upregulation of circulating CD16 + monocytes (mainly Mon2), which adhere to human umbilical vascular endothelial cells more than CD16cells, 24 thereby giving rise to a potential mechanism for monocyte migration into the failing myocardium. Furthermore, CD16 + monocytes have higher proinflammatory activity than CD16cells, and in vivo studies have demonstrated higher cytokine production by monocytes (including IL-1β, IL-8, and MCP-1) in response to MPA formation. [25] [26] [27] Consequently, MPA formation is also associated with promoting a greater inflammatory phenotype in monocytes. 24, 28 Phagocytosis is one of the most important functions of monocytes, and studies have shown that this activity is particularly marked in Mon1 and Mon2 monocytes. 13 The increased formation of MPAs in these subsets (in both AHF and SHF) might also reflect a mechanism of eliminating activated platelets from the circulation by phagocytosis. It is, therefore, possible that the high number of MPAs in HF may reflect the increased number of activated platelets found in this condition. In addition to the direct formation of MPAs, monocytes and platelets may also interact with each other to augment individual intrinsic function. For example, tissue factor release by monocytes in HF interacts with P-selectin on the surface of platelets, which results in enhanced fibrin formation. 23, 29 Patients with HF have been shown to have increased plasma MCP-1, a key monocyte chemoattractant. 30, 31 In this study there was a significant correlation between the plasma levels of MCP-1 and counts of MPA associated with nonclassic Mon3. This is perhaps in accordance with previous evidence showing the intimate role that platelets play in the regulation of monocyte recruitment to tissues. 19 In addition, these observations once more indicate very complex and context-dependent patterns of monocyte-platelet interaction. For example, the P-selectin--mediated pathway has been shown to be pivotal for monocyte aggregation with platelets in the settings of atherothrombosis but not in endotoxemia. 32 The results of our study show that increased MPA formation in Mon1 and Mon2 monocytes after acute decompensation of HF persists for ≥3 months, despite improvements in patient symptoms. Our findings suggest that the inflammatory mechanisms that activate monocytes and platelets continue many weeks after the initial event, which may contribute to the considerable morbidity and mortality seen in this patient group. Therapeutic modulation of thrombotic substrates in HF is an attractive concept, particularly in patients with AHF in whom inflammation and thrombosis are greatest. Reductions in MPAs have been demonstrated after administration of monoclonal antibodies against P-selectin glycoprotein ligand 1 and the blockade of P-selectin, 33 and although antiplatelet therapy seems to reduce MPAs, 34 anticoagulation has little effect. 35 At present, there are no convincing clinical trial data to suggest a beneficial role on mortality of either anticoagulation or antiplatelet therapy in patients with HF, unless there are concomitant indications, such as CAD or atrial fibrillation.
Limitations
The numbers of study subjects is relatively small. Although we specifically recruited HF patients with underlying CAD to draw comparisons with an appropriate control group, residual confounding may remain with some differences in clinical characteristics present between the study groups. Also, our findings should be evaluated in patients with HF because of other aetiologies, such as dilated cardiomyopathy. The functional implications of the observed changes will require further study, because it remains unclear whether MPA formation is simply a reflection of the underlying thromboinflammatory state in HF or whether they directly contribute to the pathophysiology of the disease process. Larger studies are also required to explore the use of MPAs as a risk stratifying marker for clinical outcomes in HF and to investigate the effects of using established and novel antithrombotic/anti-inflammatory drugs on both monocyte and platelet activation in this condition.
Conclusions
For the first time, we have shown that MPA formation is increased in patients with HF, and this may provide some preliminary evidence of an interaction between inflammation and thrombosis in HF. In AHF, the increase in MPAs seems to be confined to monocytes from Mon1 and Mon2 subsets, which have been shown in other studies to be proinflammatory and highly phagocytic. Also, MPAs with Mon2 seem to be negatively predictive of a worse prognosis in AHF, perhaps reflecting a beneficial role for these complexes during acute decompensation. However, larger studies powered for clinical outcomes are required to confirm whether MPAs have any prognostic role in patients with HF.
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